FINRA’s public disclosure program toll free hotline number is 1(800) 289-9999 and FINRA’s website address is: http://brokercheck.finra.org/ Public may access ...

H.C. Wainwright & Co. is one of the country’s oldest and most trusted financial institutions. To learn more about our legacy, click on a link below:

Prior to joining H.C. Wainwright, Mr. Colonnese was Director and Senior Equity Research Analyst at Cantor Fitzgerald where he led the firm’s cryptocurrency and blockchain research efforts.

H.C. Wainwright analysts pride themselves on their ability to identify compelling investment opportunities for our clients by discovering high-quality, undervalued companies before they are recognized by the market at large.

H.C. Wainwright & Co. was founded in 1868 at the Union Bank Building in Boston, Massachusetts, located at the heart of the strongest financial center in post-Civil War America.

H.C. Wainwright & Co. is one of the country’s oldest and most trusted financial institutions.

4D Molecular Therapeutics, Inc. (FDMT) 60 Degrees Pharmaceuticals, Inc. (SXTP) 89bio, Inc. (ETNB) Aadi Bioscience Inc (AADI) Abeona Therapeutics, Inc. (ABEO)

H.C. Wainwright & Co. blends traditional values with innovative services, operating with integrity and offering leading-edge investment banking, corporate finance, and strategic advisory services to public and private growth companies across multiple sectors and regions.

The H. C. Wainwright team has been the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, our team has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD transactions cumulatively since 1998.

Jul. 8, 2015 – H.C. Wainwright & Co. Ranked #1 Placement Agent for the First Half of 2015 by Sagient Research Systems; May 15, 2015 – H.C. Wainwright to Initiate Equity Research Coverage in Clean and Emerging Technologies; Feb. 9, 2015 – H.C. Wainwright Adds Fifth Senior Analyst to Its Biotechnology Equity Research Team